Table 2.
World Symposium on Pulmonary Hypertension groups 1 and 3: pulmonary hypertension medications at catheterization (diagnosis visit)*
| Overall (N = 671) | WSPH Group 1 (n = 454) | WSPH Group 3 (n = 217) | P Value | |
|---|---|---|---|---|
| Calcium channel blockers | 20 (2.0) | 16 (2.3) | 4 (1.3) | 0.329 |
| ERAs | 47 (4.7) | 36 (5.2) | 11 (3.7) | 0.320 |
| PDE-5 inhibitors | 253 (25.4) | 170 (24.3) | 83 (27.9) | 0.241 |
| Prostacyclins | 58 (5.8) | 45 (6.4) | 13 (4.4) | 0.200 |
| Inhaled nitric oxide | 72 (7.2) | 42 (6.0) | 30 (10.1) | 0.023 |
Definition of abbreviations: ERA = endothelin receptor antagonist; PDE-5 = phosphodiesterase-5; WSPH = World Symposium on Pulmonary Hypertension.
Data are shown as n (%).
*
Shown are medications used at mean 3.2 ± 16.6 and median 0.0 (interquartile range, 0.0–0.5) months from the time of diagnosis.